Inclusion Criteria:

- 18 years or older.

- Raising PSA after prior treatment failure of localized prostate cancer.

- Has a histological confirmed non-metastatic cancer of the prostate (Gleason graded)
based on the most current biopsy.

- Has a screening testosterone with-in normal range ≥1.5 ng/mL.

- Has ECOG score of ≤2.

- CT scan, MRI or bone scan report documenting no evidence of metastasis to the bone or
internal organs.

- Life expectancy of at least 15 months.

Exclusion Criteria:

- Taken hormone therapy in the last 6 months prior to entering this study.

- Has a history of sever uncontrolled asthma, anaphylactic reactions, or sever
urticaria and/or angioedema.

- Has hypersensitivity towards any component of the study drug.

- Has a previous history or presence of another malignancy other than prostate cancer
or treated squamous/basel cell carcinoma of the skin within the last five years.

- Abnormal laboratory results which in the judgement of the Investigator would affect
the patient's health or the outcome of the trial.

- Has a clinically significant medical condition (other than prostate cancer) including
but not limited to; renal, haematological, gastrointestinal, endocrine, cardiac,
neurological or psychiatric disease and alcohol or drug abuse or any other condition
which may affect the patient's health or the outcome of the trial as judged by the
Investigator.

- Has an intellectual incapacity or language barriers precluding adequate understanding
or co-operation.

- Has received an investigational drug within the last 28 days before the Screening
visit or longer if considered to possibly influence the outcome of the current trial.

- Has previously participated in any Degarelix trial.

- Is part of an ongoing trial.